EGFR and non-small cell lung carcinoma: In 2022, CRISPR system combined with post-PCR cfDNA (CRISPR-CPPC), using biotinylated gRNA and Cas9 enzyme, could enrich EGFR exon19 deletion up to 1000-fold in cfDNA samples from NSCLC patients [79].